Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

    Best Selling Products

    BioNewsCast Press Release Distribution Service

    BioNewsCast Press Release Distribution Service

     

    Vaccine Technology 2009 Conference

    Vaccine Technology 2009 Conference

     

    Veterinary Diagnostics Markets

     Veterinary Diagnostics Markets

     

    Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

    Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

     

    Royalty Financing Agreements in Pharma, Biotech and Diagnostics

    Royalty Financing Agreements in Pharma, Biotech and Diagnostics

     

    New Products

    Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

    Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

     

    Bioinformatics Market Potential

    Bioinformatics Market Potential

     

    Biotechnology in the European Union; Trends, Investing & Country Profiles

    Biotechnology in the European Union; Trends, Investing & Country Profiles

     

    China Pharmaceutical Industry: Analysis and Market Trends

    China Pharmaceutical Industry: Analysis and Market Trends

     

    European Generic Drug Market Potential

    European Generic Drug Market Potential

     

    Global Biotechnology Markets Trends

    Global Biotechnology Markets Trends

     

    Strategic Alliances in World Pharma and Biotech Markets

    Strategic Alliances in World Pharma and Biotech Markets

     

    Understanding China's Chemical Industry

    Understanding China's Chemical Industry

     

    Understanding Genomics and Global Health Impacts

    Understanding Genomics and Global Health Impacts

     

    Understanding Pharmacogenomics

    Understanding Pharmacogenomics

     

    BioPortfolio | Jain PharmaBiotech Reports |  Biomarkers - technologies, markets and companies

    Biomarkers - technologies, markets and companies

    Biomarkers - technologies, markets and companies


    This report follows the broad definition of a biomarker as a characteristic that can be objectively measured and evaluated as an indicator of normal biological or pathogenic processes as well as pharmacological responses to a therapeutic intervention. Tests based on biomarkers have been around for more than half a century, but interest in their application for diagnostics and drug discovery as well as development has increased remarkably since the beginning of the 21st century. This report describes different types of biomarkers and their discovery using various “-omics” technologies such as proteomics and metabolomics. Molecular diagnostics technologies are used for the discovery of biomarkers and new tests are also based on biomarker.

    Currently the most important applications of biomarkers are in drug discovery and development. The role of biomarkers in various therapeutic areas particularly cancer, cardiovascular diseases and disorders of the central nervous system, is described. Biomarkers are useful not only for diagnosis of some of these diseases but also for understanding the pathomechanism as well as a basis for development of therapeutics.

    Biomarkers will facilitate the combination of therapeutics with diagnostics and will thus play an important role in the development of personalized medicine. Biomarkers play a role in use of pharmacogenetics, pharmacogenomics and pharmacoproteomics for development of personalized medicine.

    Many of the regulatory issues concerning biomarkers are related to genomics, proteomics, molecular diagnostics and pharmacogenomics/pharmacogenetics. Validation of biomarkers and their role in clinical trials is discussed.

    Biomarker markets are estimated from 2007 to 2017 according to share of markets for various technologies and applications: proteomics, metabolomics, molecular diagnostics, drug discovery, clinical trials, and bioinformatics. Market values are further split according to therapeutic applications and major geographical areas. Unfulfilled needs in biomarkers are identified as well as the drivers for biomarker markets. Challenges facing the biomarker industry and strategies for developing biomarker markets are discussed.

    A large number of companies with varying technical backgrounds are involved in biomarkers and 222 of these are profiled in part 2 of the report with classification into various categories.These also include major pharmaceutical companies. There is tabulation of 483 collaborations between companies and additional academic collaborations are mentioned in the individual profiles of companies.

    Table of contents

    Introduction to biomarkers

    Technologies for Discovery of Biomarkers

    Biomarkers and Molecular Diagnostics

    Biomarkers for Drug Discovery and Development

    Role of Biomarkers in Various Diseases

    Biomarkers in Cancer

    Biomarkers of Neurological Disorders

    Biomarkers of Cardiovascular Disorders

    Biomarkers and Personalized Medicine

    Regulatory issues

    Markets for Biomarkers

    Companies

    August 2009.. 939 Pages, Tables 57, Figures 12, Companies 259, Alliances 483, References 750


    Table of Contents
    Full Table of Contents (doc)

    Price



    BioPortfolio uses RBS Worldpay Secure Server for credit card transactions